| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view
|
NEVEN, P.
|
|
2006
|
|
s2 |
p. 505-510
|
artikel
|
| 2 |
ANDROGENS AND BREAST CANCER
|
Franco, B.
|
|
2006
|
|
s2 |
p. 493
|
artikel
|
| 3 |
An estrogen receptor α-dependent regulation of estrogen receptor–related receptor α in the proliferation of endometrial carcinoma cells
|
SUN, P.-M.
|
|
2006
|
|
s2 |
p. 564-568
|
artikel
|
| 4 |
ANTHROPOMETRY, PHYSICAL ACTIVITY, AND ENDOMETRIAL CANCER RISK: RESULTS FROM THE NETHERLANDS COHORT STUDY
|
Schouten, L.J.
|
|
2006
|
|
s2 |
p. 492
|
artikel
|
| 5 |
An update on breast cancer prevention trials
|
WICKERHAM, D.L.
|
|
2006
|
|
s2 |
p. 498-501
|
artikel
|
| 6 |
An update on ovarian suppression/ablation
|
JAKESZ, R.
|
|
2006
|
|
s2 |
p. 511-514
|
artikel
|
| 7 |
An update on raloxifene
|
Draper, M.W.
|
|
2006
|
|
s2 |
p. 502-503
|
artikel
|
| 8 |
Association between the CHEK2*1100delC germ line mutation and estrogen receptor status
|
de BOCK , G.H.
|
|
2006
|
|
s2 |
p. 552-555
|
artikel
|
| 9 |
Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself
|
CARDOSO, F.
|
|
2006
|
|
s2 |
p. 533-537
|
artikel
|
| 10 |
Bone safety of aromatase inhibitors versus tamoxifen
|
LØNNING, P.E.
|
|
2006
|
|
s2 |
p. 518-520
|
artikel
|
| 11 |
Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor–positive early breast cancer. Analysis based on the ATAC trial
|
MOEREMANS, K.
|
|
2006
|
|
s2 |
p. 576-578
|
artikel
|
| 12 |
Effects of 17β-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messengerRNA in breast cancer cells
|
MIRKIN, S.
|
|
2006
|
|
s2 |
p. 560-563
|
artikel
|
| 13 |
Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26–28, 2006
|
NEVEN, P.
|
|
2006
|
|
s2 |
p. 479-491
|
artikel
|
| 14 |
Endometrial cancer: predictors of response and preferred endocrine therapy
|
AMANT, F.
|
|
2006
|
|
s2 |
p. 527-528
|
artikel
|
| 15 |
Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients
|
MORALES, L.
|
|
2006
|
|
s2 |
p. 515-517
|
artikel
|
| 16 |
Exogenous steroids for menopausal symptoms and breast/endometrial cancer risk
|
MOURITS, M.J.E.
|
|
2006
|
|
s2 |
p. 494-496
|
artikel
|
| 17 |
Gene expression profiling of treatment resistance: hype or hope for therapeutic target identification
|
HELLEMAN, J.
|
|
2006
|
|
s2 |
p. 538-542
|
artikel
|
| 18 |
Growth patterns and the risk of breast cancer in women
|
AHLGREN, M.
|
|
2006
|
|
s2 |
p. 569-575
|
artikel
|
| 19 |
How to measure and report the estrogen (and progesterone) receptor in breast cancer
|
VERMEULEN, P.B.
|
|
2006
|
|
s2 |
p. 529-532
|
artikel
|
| 20 |
Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families
|
Jernström, H.
|
|
2006
|
|
s2 |
p. 497
|
artikel
|
| 21 |
Interleukin-1α protein secretion in breast cancer is associated with poor differentiation and estrogen receptorα negativity
|
SINGER, C.F.
|
|
2006
|
|
s2 |
p. 556-559
|
artikel
|
| 22 |
Is cancer risk related to genes for steroid receptors and estrogen metabolism?
|
LEGIUS, E.
|
|
2006
|
|
s2 |
p. 549-551
|
artikel
|
| 23 |
Is fulvestrant (“Faslodex”) just another selective estrogen receptor modulator?
|
HOWELL, A.
|
|
2006
|
|
s2 |
p. 521-523
|
artikel
|
| 24 |
Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant
|
VERGOTE, I.
|
|
2006
|
|
s2 |
p. 524-526
|
artikel
|
| 25 |
Not all selective estrogen response modulators are created equal: update on lasofoxifene
|
Goldstein, S.R.
|
|
2006
|
|
s2 |
p. 504
|
artikel
|
| 26 |
Oral Abstracts
|
|
|
2006
|
|
s2 |
p. 579-588
|
artikel
|
| 27 |
Poster Presentations
|
|
|
2006
|
|
s2 |
p. 589-598
|
artikel
|
| 28 |
Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists
|
JOHNSTON, S.R.D.
|
|
2006
|
|
s2 |
p. 543-548
|
artikel
|
Tijdschrift beschrijving